Your browser doesn't support javascript.
loading
Survival outcomes of patients with subglottic squamous cell carcinoma : a study of the National Cancer Database.
Shi, Lucy L; McMullen, Caitlin; Vorwald, Kathryn; Nichols, Anthony C; MacNeil, S Danielle; Wadsworth, J Trad; Chung, Christine H; Wang, Xuefeng; Patel, Krupal B.
Afiliação
  • Shi LL; Department of Otolaryngology-Head and Neck Surgery, The Ohio State University, Columbus, OH, USA.
  • McMullen C; Department of Head and Neck-Endocrine Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
  • Vorwald K; Department of Head and Neck-Endocrine Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
  • Nichols AC; Department of Otolaryngology-Head and Neck Surgery, Western University, London, ON, Canada.
  • MacNeil SD; Department of Otolaryngology-Head and Neck Surgery, Western University, London, ON, Canada.
  • Wadsworth JT; Department of Head and Neck-Endocrine Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
  • Chung CH; Department of Head and Neck-Endocrine Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
  • Wang X; Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
  • Patel KB; Department of Head and Neck-Endocrine Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA. krupal.patel@moffitt.org.
Eur Arch Otorhinolaryngol ; 278(12): 4923-4932, 2021 Dec.
Article em En | MEDLINE | ID: mdl-33646344
BACKGROUND: Subglottic squamous cell carcinoma (SCC) represents less than 5% of all laryngeal cancers. Our objective was to better characterize survival using the National Cancer Database (NCDB) registry from 2004 to 2015. RESULTS: 403 patients met inclusion criteria. 63.8% presented with advanced-stage disease. Treatment regimens were as follows: 15.9% underwent surgery alone, 16.9% underwent surgery followed by adjuvant therapy, and 67.2% underwent primary chemo/radiation (C/RT). Five-year overall survival (OS) was 58.6% for Stage I and II patients, 49.1% for Stage III, and 36.3% for stage IV. Adjusted OS for all-stage patients was worse with C/RT compared to upfront surgery (40.6% vs. 58.4%; HR 1.83 [95%CI 1.29-2.61] p < 0.001) and adjusted OS for stage 4 disease was significantly worse with C/RT compared to surgery (26.0% vs. 45.2%, HR 1.79 [95%CI 1.17-2.73] p = 0.007). CONCLUSION: Majority of patients were treated with primary C/RT. Adjusted survival favors upfront surgery versus C/RT, especially in patients with Stage IV disease.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma de Células Escamosas / Neoplasias Laríngeas / Neoplasias de Cabeça e Pescoço Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma de Células Escamosas / Neoplasias Laríngeas / Neoplasias de Cabeça e Pescoço Idioma: En Ano de publicação: 2021 Tipo de documento: Article